WEBULL
News
PDSB
0.7111
-0.32%
-0.0023
Weekly Report: what happened at PDSB last week (0202-0206)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 02/04 12:05
Weekly Report: what happened at PDSB last week (0126-0130)?
Weekly Report · 02/02 09:06
PDS Biotechnology Highlights Promising Phase 2 Prostate Cancer Data
TipRanks · 01/28 14:18
PDS announces presentation of preliminary Phase 2 results on PDS01ADC
TipRanks · 01/28 13:56
PDS Biotechnology Presents Results Of National Cancer Institute-Led Study Of Investigational Interleukin-12 Tumor Targeted Immunocytokine, PDS01ADC, At AACR Special Conference
Benzinga · 01/28 13:48
PDS Biotech Reports Promising Phase 2 Results for PDS01ADC in Metastatic Prostate Cancer
Reuters · 01/28 13:45
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
Barchart · 01/28 07:45
Weekly Report: what happened at PDSB last week (0119-0123)?
Weekly Report · 01/26 09:06
PDS Biotechnology Secures Key Patent Strengthening PDS0101 Protection
TipRanks · 01/22 14:18
PDS Biotechnology announces new U.S. patent covering tech underlying PDS0101
TipRanks · 01/22 13:50
PDS Biotechnology Announces U.S. Patent Office Issues Notice Of Allowance For Its PDS0101 Asset
Benzinga · 01/22 13:46
PDS Biotechnology Receives Notice of Allowance for New U.S. Patent Covering PDS0101 Technology
Reuters · 01/22 13:45
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
Barchart · 01/22 07:45
Weekly Report: what happened at PDSB last week (0112-0116)?
Weekly Report · 01/19 09:07
Weekly Report: what happened at PDSB last week (0105-0109)?
Weekly Report · 01/12 09:07
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 01/09 21:05
PDS Biotechnology Updates Phase 3 Trial Design for PDS0101
TipRanks · 01/09 14:19
BUZZ-PDS Biotech rises as it seeks faster FDA nod for cancer drug
Reuters · 01/09 14:04
PDS Biotechnology announces FDA alignment on use of PFS as primary endpoint
TipRanks · 01/09 13:52
More
Webull provides a variety of real-time PDSB stock news. You can receive the latest news about Pds Biotechnology Corporation through multiple platforms. This information may help you make smarter investment decisions.
About PDSB
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.